James Dean
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
James Dean has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Dave Singh
Medicines Evaluation Unit, Manchester, United Kingdom
16 shared publicationsAugusta Beech
Division of Immunology, Immunity to infection and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK
4 shared publications- Augusta Beech
Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK
3 shared publications Daniel Hamer
Medicines Evaluation Unit, Manchester, United Kingdom
3 shared publicationsNatalie Jackson
Medicines Evaluation Unit, Manchester University NHS Foundation Trust, Manchester, UK
3 shared publicationsStephen Fowler
University of Manchester, Manchester, United Kingdom
3 shared publications
Latest Publications
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA4831
Lung mechanics in PRISm patients measured by a novel spirometry parameter
Preserved ratio impaired spirometry (PRISm) is characterised by normal FEV1/FVC but reduced FEV1. This spirometry pattern can occur from early small airway disease (SAD) or from small lung size (i.e. restrictive pattern). The concavity of the flow volume curve is suggested to be related to SAD, and this can be calculated using Area of Obstruction (Ao), where the area above the flow volume curve is divided by the area of the triangle between PEF and FVC (Lee et al., 2016); Values approaching 1 represent increasing concavity. We assessed whether Ao could identify a PRISm phenotype with evidence of SAD. Nineteen patients with PRISm performed spirometry, oscillometry and plethysmography. Evidence of SAD was measured as a loss of elasticity in the small airways, as oscillometric reactance area (AX) z-score ≥1.645. Groups were compared using t-tests or Mann-Whitney tests. Multiple linear regression was performed to determine whether loss of elasticity and/or lung size predicted spirometry results. In PRISm patients with loss of small airway elasticity (n=11), FEV1/FVC was lower (median[IQR] z-score: -1.24 [-0.68,-1.36] vs -0.53 [-0.67,0.09], p=0.0068), whereas FEV1 was not (p>0.05). These patients also had greater concavity of the flow volume curve (mean[95%CI] Ao: 0.36 [0.28,0.44] vs 0.19 [0.10,0.28], p=0.0061). Concavity was predicted solely by small airway elasticity (AX: β estimate = 0.05, p=0.0243), whereas FEV1/FVC ratio was predicted by both small lungs (TLC: β estimate = -0.29, p=0.0046) and small airway elasticity (AX: β estimate = -0.21, p=0.0141). The concavity of the flow volume curve, measured by Ao, can identify PRISm patients with loss of elastic recoil, irrespective of lung size, and may identify a phenotype characterised by small airway disease.
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA4831
Lung mechanics in PRISm patients measured by a novel spirometry parameter
Preserved ratio impaired spirometry (PRISm) is characterised by normal FEV1/FVC but reduced FEV1. This spirometry pattern can occur from early small airway disease (SAD) or from small lung size (i.e. restrictive pattern). The concavity of the flow volume curve is suggested to be related to SAD, and this can be calculated using Area of Obstruction (Ao), where the area above the flow volume curve is divided by the area of the triangle between PEF and FVC (Lee et al., 2016); Values approaching 1 represent increasing concavity. We assessed whether Ao could identify a PRISm phenotype with evidence of SAD. Nineteen patients with PRISm performed spirometry, oscillometry and plethysmography. Evidence of SAD was measured as a loss of elasticity in the small airways, as oscillometric reactance area (AX) z-score ≥1.645. Groups were compared using t-tests or Mann-Whitney tests. Multiple linear regression was performed to determine whether loss of elasticity and/or lung size predicted spirometry results. In PRISm patients with loss of small airway elasticity (n=11), FEV1/FVC was lower (median[IQR] z-score: -1.24 [-0.68,-1.36] vs -0.53 [-0.67,0.09], p=0.0068), whereas FEV1 was not (p>0.05). These patients also had greater concavity of the flow volume curve (mean[95%CI] Ao: 0.36 [0.28,0.44] vs 0.19 [0.10,0.28], p=0.0061). Concavity was predicted solely by small airway elasticity (AX: β estimate = 0.05, p=0.0243), whereas FEV1/FVC ratio was predicted by both small lungs (TLC: β estimate = -0.29, p=0.0046) and small airway elasticity (AX: β estimate = -0.21, p=0.0141). The concavity of the flow volume curve, measured by Ao, can identify PRISm patients with loss of elastic recoil, irrespective of lung size, and may identify a phenotype characterised by small airway disease.
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA1746
Using novel flow volume curve analysis to improve spirometry quality
Spirometry requires maximal forced exhalation, but no standard exists for quantifying patient effort. Submaximal effort can lead to falsely high FEV1 values (figure 1) through limiting dynamic compression of the airways, especially in lung conditions with loss of elasticity. erj;68/suppl_70/PA1746/F1 F1 F1 We investigated if similarity between flow volume curves could quantify spirometry effort and assessed its impact on FEV1 variability. Thirty eight COPD patients were assessed. Each curve from a spirometry session was exported and aligned on the volume axis to the curve with the highest PEF. The coefficient of determination (R2) was used to assess the similarity between curves, across the 1st litre exhaled, known as the effort dependent region of the flow volume curve. FEV1 and its range was compared between all curves and after discarding those with an R2 value 2 value 0.95 (mean[range] reduction in variability = -75 [-380,0] mls, p1 value (median[range] reduction= -10 [-130,0] mls, p<0.0001). Spirometry accuracy can be improved by quantifying the similarity between flow volume curves, excluding those with a coefficient of determination below 0.95. This is a simple way to automate spirometry quality, for both diagnostic purposes and for improving clinical trial data quality.
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA1746
Using novel flow volume curve analysis to improve spirometry quality
Spirometry requires maximal forced exhalation, but no standard exists for quantifying patient effort. Submaximal effort can lead to falsely high FEV1 values (figure 1) through limiting dynamic compression of the airways, especially in lung conditions with loss of elasticity. erj;68/suppl_70/PA1746/F1 F1 F1 We investigated if similarity between flow volume curves could quantify spirometry effort and assessed its impact on FEV1 variability. Thirty eight COPD patients were assessed. Each curve from a spirometry session was exported and aligned on the volume axis to the curve with the highest PEF. The coefficient of determination (R2) was used to assess the similarity between curves, across the 1st litre exhaled, known as the effort dependent region of the flow volume curve. FEV1 and its range was compared between all curves and after discarding those with an R2 value 2 value 0.95 (mean[range] reduction in variability = -75 [-380,0] mls, p1 value (median[range] reduction= -10 [-130,0] mls, p<0.0001). Spirometry accuracy can be improved by quantifying the similarity between flow volume curves, excluding those with a coefficient of determination below 0.95. This is a simple way to automate spirometry quality, for both diagnostic purposes and for improving clinical trial data quality.
- Open Access
- 9 July 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (5)
Is full inhalation during spirometry inhibited by COPD Pathophysiology?
Extract The diagnosis of chronic obstructive pulmonary disease (COPD) requires confirmation by spirometry; a post-bronchodilator forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio <0.7 indicates the presence of airflow obstruction [1]. The manoeuvre must be performed from total lung capacity (TLC) to ensure accurate results [2]. Patients are coached to inhale fully after completion of the forced exhalation, known as a forced inhaled vital capacity (FIVC). The test is deemed unacceptable if the FIVC is significantly larger than the linked FVC (known as an FIVC-FVC error). The incidence of FIVC-FVC error in COPD patients has not been documented. It has been reported that COPD patients can fail the FIVC-FVC criterion despite coaching and correction of technique [3]. This suggests that both pathophysiological features of COPD and errors in technique may impact the ability to repeatedly reach TLC during the spirometry manoeuvre.
- 9 July 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (5)
Open AccessIs full inhalation during spirometry inhibited by COPD Pathophysiology?
Extract The diagnosis of chronic obstructive pulmonary disease (COPD) requires confirmation by spirometry; a post-bronchodilator forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio <0.7 indicates the presence of airflow obstruction [1]. The manoeuvre must be performed from total lung capacity (TLC) to ensure accurate results [2]. Patients are coached to inhale fully after completion of the forced exhalation, known as a forced inhaled vital capacity (FIVC). The test is deemed unacceptable if the FIVC is significantly larger than the linked FVC (known as an FIVC-FVC error). The incidence of FIVC-FVC error in COPD patients has not been documented. It has been reported that COPD patients can fail the FIVC-FVC criterion despite coaching and correction of technique [3]. This suggests that both pathophysiological features of COPD and errors in technique may impact the ability to repeatedly reach TLC during the spirometry manoeuvre.
- Open Access
- 5 July 2025
- Published by Springer Nature in Lung
- Vol. 203 (1) , 1-9
The Advantages of FEV1 Percent Predicted Change During Bronchial Challenge Testing
Background: The methacholine challenge requires a 20% fall in forced expiratory volume in one second (FEV 1 ). The fall is measured as litre (L) change from the pre-challenge (baseline) value. A higher baseline FEV 1 requires a greater volume change to reach a 20% fall. The aim of this study was to evaluate change using percent predicted, which may remove dependence on the baseline value. Methods: Challenge data from a cohort of 114 asthma patients was re-analysed. The dose causing an 20% fall from baseline (PD 20 ) was compared to a 15% fall in predicted value (PD 15% ) for the classification of bronchial hyperresponsiveness. Results: There was significant agreement between PD 20 and PD 15% (r = 0.95, p < 0.0001), with an ICC of 0.97. PD 20 was significantly higher than PD 15 % (0.0055 mg, p < 0.0001). Greater decreases in FEV 1 were observed with PD 20 versus PD 15% (21.4% pred vs 19.1% pred respectively, p = 0.0004), with 29% of patients requiring at least one additional dose of methacholine to achieve PD 20 compared to PD 15% . A higher baseline FEV 1 resulted in higher PD 20 values, whereas no relationship was found for PD 15% . Variability in FEV 1 between repeated visits (n = 15) was associated with the change in PD 20 , but not the change in PD 15% . Conclusion: We suggest a PD criteria based on 15% predicted change should be used for bronchial challenge testing. This method is less influenced by baseline airflow obstruction, and is a more efficient and safer way of measuring airway hyperresponsiveness.
- 5 July 2025
- Published by Springer Nature in Lung
- Vol. 203 (1) , 1-9
Open AccessThe Advantages of FEV1 Percent Predicted Change During Bronchial Challenge Testing
Background: The methacholine challenge requires a 20% fall in forced expiratory volume in one second (FEV 1 ). The fall is measured as litre (L) change from the pre-challenge (baseline) value. A higher baseline FEV 1 requires a greater volume change to reach a 20% fall. The aim of this study was to evaluate change using percent predicted, which may remove dependence on the baseline value. Methods: Challenge data from a cohort of 114 asthma patients was re-analysed. The dose causing an 20% fall from baseline (PD 20 ) was compared to a 15% fall in predicted value (PD 15% ) for the classification of bronchial hyperresponsiveness. Results: There was significant agreement between PD 20 and PD 15% (r = 0.95, p < 0.0001), with an ICC of 0.97. PD 20 was significantly higher than PD 15 % (0.0055 mg, p < 0.0001). Greater decreases in FEV 1 were observed with PD 20 versus PD 15% (21.4% pred vs 19.1% pred respectively, p = 0.0004), with 29% of patients requiring at least one additional dose of methacholine to achieve PD 20 compared to PD 15% . A higher baseline FEV 1 resulted in higher PD 20 values, whereas no relationship was found for PD 15% . Variability in FEV 1 between repeated visits (n = 15) was associated with the change in PD 20 , but not the change in PD 15% . Conclusion: We suggest a PD criteria based on 15% predicted change should be used for bronchial challenge testing. This method is less influenced by baseline airflow obstruction, and is a more efficient and safer way of measuring airway hyperresponsiveness.
- Open Access
- 3 October 2024
- Published by Springer Nature in Respiratory Research
- Vol. 25 (1) , 1-10
Expiratory flow limitation development index (ELDI): a novel method of assessing respiratory mechanics in COPD
Background: Expiratory flow limitation (EFL) can be detected using oscillometric reactance and is associated with a worse clinical presentation in chronic obstructive pulmonary disease (COPD). Reactance can show negative swings upon exhalation, which may develop at different rates between patients. We propose a new method to quantify the rate of EFL development; the EFL Development Index (ELDI). Methods: A retrospective analysis of data from 124 COPD patients was performed. Data included lung function tests, Impulse Oscillometry (IOS), St Georges Respiratory Questionnaire (SGRQ), modified Medical Research Council (mMRC) scale and COPD Assessment Test (CAT) score. Fifty four patients had repeat data after 6 months. Twenty two patients had data recorded after 5 days of treatment with long acting bronchodilator therapy. EDLI was calculated as the mean expiratory reactance divided by the minimum expiratory reactance. Results: The mean ELDI was used to categorise patients with rapid onset of EFL (> 0.63; n = 29) or gradual onset (≤ 0.63; n = 34). Those with rapid development had worse airflow obstruction, lower quality of life scores, and greater resting hyperinflation, compared to those with gradual development. In patients with EFL, ELDI correlated with symptoms scores, airflow obstruction, lung volumes and gas diffusion. Both EFL and ELDI were stable over 6 months. EFL and EDLI improved with bronchodilator treatment. Conclusions: COPD patients with rapid EFL development (determined by ELDI) had worse clinical characteristics than those with gradual EFL development. The rate of EFL development appears to be associated with clinical and physiological characteristics.
- 3 October 2024
- Published by Springer Nature in Respiratory Research
- Vol. 25 (1) , 1-10
Open AccessExpiratory flow limitation development index (ELDI): a novel method of assessing respiratory mechanics in COPD
Background: Expiratory flow limitation (EFL) can be detected using oscillometric reactance and is associated with a worse clinical presentation in chronic obstructive pulmonary disease (COPD). Reactance can show negative swings upon exhalation, which may develop at different rates between patients. We propose a new method to quantify the rate of EFL development; the EFL Development Index (ELDI). Methods: A retrospective analysis of data from 124 COPD patients was performed. Data included lung function tests, Impulse Oscillometry (IOS), St Georges Respiratory Questionnaire (SGRQ), modified Medical Research Council (mMRC) scale and COPD Assessment Test (CAT) score. Fifty four patients had repeat data after 6 months. Twenty two patients had data recorded after 5 days of treatment with long acting bronchodilator therapy. EDLI was calculated as the mean expiratory reactance divided by the minimum expiratory reactance. Results: The mean ELDI was used to categorise patients with rapid onset of EFL (> 0.63; n = 29) or gradual onset (≤ 0.63; n = 34). Those with rapid development had worse airflow obstruction, lower quality of life scores, and greater resting hyperinflation, compared to those with gradual development. In patients with EFL, ELDI correlated with symptoms scores, airflow obstruction, lung volumes and gas diffusion. Both EFL and ELDI were stable over 6 months. EFL and EDLI improved with bronchodilator treatment. Conclusions: COPD patients with rapid EFL development (determined by ELDI) had worse clinical characteristics than those with gradual EFL development. The rate of EFL development appears to be associated with clinical and physiological characteristics.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA1165
Expiratory Flow Limitation Development Index (EDI) measured by oscillometry in COPD
Chronic obstructive pulmonary disease (COPD) patients with expiratory flow limitation (EFL) display greater hyperinflation and gas trapping. Oscillometry reactance measurements quantify EFL. Negative swings in reactance, indicating EFL onset, can develop near exhalation onset (rapid EFL) or later (gradual EFL) at lower lung volumes. We propose a new method to quantify this; the EFL Development Index (EDI). Aim: To assess the clinical utility of the EDI in COPD patients. Lung function, oscillometry and respiratory questionnaire data were collected. EFL was the maximum reactance change during tidal breathing (X5peak-peak ≥0.59 kPa/L/s). EDI was calculated during exhalation as mean reactance divided by minimum reactance; values closer to 1 indicate more rapid EFL development. COPD patients with EFL were recruited (n = 63). Mean EDI was 0.63; values below this were categorised as EFLgradual (n = 34) and above as EFLrapid (n = 29). EFL was similar between groups (X5peak-peak and ∆X5; p >0.05). EFLrapid patients had lower forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) ratio values (median: 0.36 vs 0.50), higher St Georges Respiratory Questionnaire (SGRQ) impact scores (mean: 51 vs 38), higher functional residual capacity (FRC) values (median: 145% vs 110%) and higher residual volume (RV) values (mean: 161% vs 144%), all p 0.05). Rapid EFL development was associated with more severe disease, worse gas trapping with hyperinflation, and a worse quality of life. EDI may be a useful marker of EFL severity that is not detected by other oscillometry measurements.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA1165
Expiratory Flow Limitation Development Index (EDI) measured by oscillometry in COPD
Chronic obstructive pulmonary disease (COPD) patients with expiratory flow limitation (EFL) display greater hyperinflation and gas trapping. Oscillometry reactance measurements quantify EFL. Negative swings in reactance, indicating EFL onset, can develop near exhalation onset (rapid EFL) or later (gradual EFL) at lower lung volumes. We propose a new method to quantify this; the EFL Development Index (EDI). Aim: To assess the clinical utility of the EDI in COPD patients. Lung function, oscillometry and respiratory questionnaire data were collected. EFL was the maximum reactance change during tidal breathing (X5peak-peak ≥0.59 kPa/L/s). EDI was calculated during exhalation as mean reactance divided by minimum reactance; values closer to 1 indicate more rapid EFL development. COPD patients with EFL were recruited (n = 63). Mean EDI was 0.63; values below this were categorised as EFLgradual (n = 34) and above as EFLrapid (n = 29). EFL was similar between groups (X5peak-peak and ∆X5; p >0.05). EFLrapid patients had lower forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) ratio values (median: 0.36 vs 0.50), higher St Georges Respiratory Questionnaire (SGRQ) impact scores (mean: 51 vs 38), higher functional residual capacity (FRC) values (median: 145% vs 110%) and higher residual volume (RV) values (mean: 161% vs 144%), all p 0.05). Rapid EFL development was associated with more severe disease, worse gas trapping with hyperinflation, and a worse quality of life. EDI may be a useful marker of EFL severity that is not detected by other oscillometry measurements.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA3951
Novel spirometric parameters and small airway disease in COPD
Background: Chronic obstructive pulmonary disease (COPD) is characterised by progressive small airway disease (SAD), resulting in increased small airway resistance and gas trapping. Spirometric SAD is measured as the flow during the middle portion of the test (FEF25%-75%). Characteristics of the flow-volume loop (FVL) can also be calculated, such as size or shape, that may have a role in assessing SAD. Aim: To compare alternative spirometric parameters with FEF25%-75% for markers of SAD in COPD. Methods: Spirometry data from 111 patients with COPD (GOLD 1-4) was assessed. Alternative parameters assessed the size (area, AFV%) and shape (area of obstruction, Ao%AR) of the FVL. We propose novel parameters that assess the mid (3rd and 4th quartile area, AFVQ3+Q4%) and end (volume exhaled between 0.5 and 0.1 L/s, Vf0.1-0.5%FVC) regions of the FVL. Associations with small airway resistance (R5-R20) and gas trapping (residual volume/total lung capacity, RV/TLC) were performed using spearman rho, with p 5-R20 and RV/TLC data, respectively. Results are shown in table 1. All parameters were moderately associated with small airway resistance, other than a weak association for Vf0.1-0.5%FVC. All parameters showed a good association with gas trapping. R5-R20 and RV/TLC were associated (rho = 0.38, p 5-R20 RV/TLC rho rho FEV1% −0.49 −0.61 FEF25%-75%% −0.41 −0.61 AFV% −0.51 −0.71 Ao%AR 0.53 0.71 AFVQ3+Q4% −0.46 −0.65 Vf0.1-0.5%FVC 0.32 0.56
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA3951
Novel spirometric parameters and small airway disease in COPD
Background: Chronic obstructive pulmonary disease (COPD) is characterised by progressive small airway disease (SAD), resulting in increased small airway resistance and gas trapping. Spirometric SAD is measured as the flow during the middle portion of the test (FEF25%-75%). Characteristics of the flow-volume loop (FVL) can also be calculated, such as size or shape, that may have a role in assessing SAD. Aim: To compare alternative spirometric parameters with FEF25%-75% for markers of SAD in COPD. Methods: Spirometry data from 111 patients with COPD (GOLD 1-4) was assessed. Alternative parameters assessed the size (area, AFV%) and shape (area of obstruction, Ao%AR) of the FVL. We propose novel parameters that assess the mid (3rd and 4th quartile area, AFVQ3+Q4%) and end (volume exhaled between 0.5 and 0.1 L/s, Vf0.1-0.5%FVC) regions of the FVL. Associations with small airway resistance (R5-R20) and gas trapping (residual volume/total lung capacity, RV/TLC) were performed using spearman rho, with p 5-R20 and RV/TLC data, respectively. Results are shown in table 1. All parameters were moderately associated with small airway resistance, other than a weak association for Vf0.1-0.5%FVC. All parameters showed a good association with gas trapping. R5-R20 and RV/TLC were associated (rho = 0.38, p 5-R20 RV/TLC rho rho FEV1% −0.49 −0.61 FEF25%-75%% −0.41 −0.61 AFV% −0.51 −0.71 Ao%AR 0.53 0.71 AFVQ3+Q4% −0.46 −0.65 Vf0.1-0.5%FVC 0.32 0.56
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , OA4588
Using % predicted change during bronchial challenge testing to remove bias
The methacholine challenge assesses bronchial hyper-reactivity, reporting the provocative dose causing a 20% fall in FEV1 (PD20). Patients with low baseline values require a smaller volume fall compared to those with higher baseline values, introducing bias. Change in % predicted has been advocated for reversibility testing to remove this bias, but this has not been employed in bronchial challenge testing. Aim: To evaluate % predicted decrease during bronchial challenge. Data from 15 asthma patients was assessed. Methacholine challenge was performed as per ERS 2017 guidelines, utilising a 20 second protocol with a jet nebuliser (AeroEclipse BAN II). Change in % predicted was calculated at each dose as ((FEV1meth-FEV1pre)*100)/FEV1pred. PD values based on fall in % predicted were compared to PD20 using Wilcoxon test, with p < 0.05 considered significant. The fall in % predicted that equated to a 20% fall from baseline (figure 1) ranged from 14.7% to 22.2%. A PD value using a 15% fall in predicted was significantly lower than PD20 (median: 14µg vs 21µg, p = 0.0002), and would have resulted in 3 patients requiring one less dose of methacholine. Using % predicted value may reduce bias in bronchial challenge testing, whilst maintaining discriminatory capability for hyper-reactivity. erj;64/suppl_68/OA4588/F1 F1 F1 Figure 1. Grey bars – fall in % predicted that equated to a 20% fall from baseline FEV1. Grey lines - actual fall in % predicted at consecutive methacholine doses.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , OA4588
Using % predicted change during bronchial challenge testing to remove bias
The methacholine challenge assesses bronchial hyper-reactivity, reporting the provocative dose causing a 20% fall in FEV1 (PD20). Patients with low baseline values require a smaller volume fall compared to those with higher baseline values, introducing bias. Change in % predicted has been advocated for reversibility testing to remove this bias, but this has not been employed in bronchial challenge testing. Aim: To evaluate % predicted decrease during bronchial challenge. Data from 15 asthma patients was assessed. Methacholine challenge was performed as per ERS 2017 guidelines, utilising a 20 second protocol with a jet nebuliser (AeroEclipse BAN II). Change in % predicted was calculated at each dose as ((FEV1meth-FEV1pre)*100)/FEV1pred. PD values based on fall in % predicted were compared to PD20 using Wilcoxon test, with p < 0.05 considered significant. The fall in % predicted that equated to a 20% fall from baseline (figure 1) ranged from 14.7% to 22.2%. A PD value using a 15% fall in predicted was significantly lower than PD20 (median: 14µg vs 21µg, p = 0.0002), and would have resulted in 3 patients requiring one less dose of methacholine. Using % predicted value may reduce bias in bronchial challenge testing, whilst maintaining discriminatory capability for hyper-reactivity. erj;64/suppl_68/OA4588/F1 F1 F1 Figure 1. Grey bars – fall in % predicted that equated to a 20% fall from baseline FEV1. Grey lines - actual fall in % predicted at consecutive methacholine doses.
- Open Access
- 23 November 2023
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 9 (6)
Exhaled nitric oxide, eosinophils and current smoking in COPD patients
There is increasing interest in type 2 (T2) inflammation in COPD [1]. COPD patients with higher blood eosinophil counts (BECs) have a greater T2 profile, including interleukin (IL)-13 expression, in bronchial brush and sputum samples [2–4]. IL-13 upregulates inducible nitric oxide synthase, increasing fractional exhaled nitric oxide (FENO) levels.
- 23 November 2023
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 9 (6)
Open AccessExhaled nitric oxide, eosinophils and current smoking in COPD patients
There is increasing interest in type 2 (T2) inflammation in COPD [1]. COPD patients with higher blood eosinophil counts (BECs) have a greater T2 profile, including interleukin (IL)-13 expression, in bronchial brush and sputum samples [2–4]. IL-13 upregulates inducible nitric oxide synthase, increasing fractional exhaled nitric oxide (FENO) levels.
- Open Access
- 1 November 2023
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 18, 2555-2563
Investigation of the Methodology of Specific Airway Resistance Measurements in COPD
Introduction: Specific resistance (SRaw) measurements in Chronic Obstructive Pulmonary Disease (COPD) patients may be performed by panting or tidal breathing. The aim of this study was to compare how breathing frequency affected SRaw in COPD and compare different tangent plotting methods. Methods: Fifteen COPD patients participated. Three protocols were performed: tidal 1 – spontaneous tidal breathing; tidal 2 – tidal breathing with a flow of ± 1 L/sec; panting – 60 breaths per min. Effective (SReff), total (SRtot), ± 0.5 L/s (SR0.5), and mid (SRmid) specific resistance were assessed. Results: The tidal breathing protocols provided similar results. Panting resulted in higher SReff (p = 0.0002) and SRtot (p < 0.0001) versus tidal breathing, but not SR0.5 or SRmid. Breathing frequency did not affect intra-test variance. SReff and SRtot measurements were similar, and were higher than SR0.5, during tidal breathing (p = 0.0014 and p < 0.0001 respectively) and panting (p = 0.0179 and p < 0.0001 respectively). SRtot was higher than SRmid during tidal breathing (p < 0.0001) and panting (p < 0.0001). Intra-test variance of SReff and SRtot were similar and showed the lowest percent coefficient of variation during both tidal breathing and panting. Conclusion: Panting and tidal breathing manoeuvres are not interchangeable in COPD patients. Panting widens the clubbing in the SRaw loop. SR0.5 and SRmid may underestimate abnormal physiology in COPD. Plain Language Summary: The effort to breathe can be measured as specific airway resistance (SRaw), which is a measure of the airflow that a person can achieve. SRaw is calculated from a plotted loop, but may be affected by the way that the test is performed and calculated. SRaw can be measured during panting or tidal breathing, and can be calculated using different methods of plotting the SRaw slope. In COPD patients, we found that panting SRaw is higher than during tidal breathing, and the calculation methods that use the extremities of the SRaw loop give higher values and have the lowest variability.
- 1 November 2023
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 18, 2555-2563
Open AccessInvestigation of the Methodology of Specific Airway Resistance Measurements in COPD
Introduction: Specific resistance (SRaw) measurements in Chronic Obstructive Pulmonary Disease (COPD) patients may be performed by panting or tidal breathing. The aim of this study was to compare how breathing frequency affected SRaw in COPD and compare different tangent plotting methods. Methods: Fifteen COPD patients participated. Three protocols were performed: tidal 1 – spontaneous tidal breathing; tidal 2 – tidal breathing with a flow of ± 1 L/sec; panting – 60 breaths per min. Effective (SReff), total (SRtot), ± 0.5 L/s (SR0.5), and mid (SRmid) specific resistance were assessed. Results: The tidal breathing protocols provided similar results. Panting resulted in higher SReff (p = 0.0002) and SRtot (p < 0.0001) versus tidal breathing, but not SR0.5 or SRmid. Breathing frequency did not affect intra-test variance. SReff and SRtot measurements were similar, and were higher than SR0.5, during tidal breathing (p = 0.0014 and p < 0.0001 respectively) and panting (p = 0.0179 and p < 0.0001 respectively). SRtot was higher than SRmid during tidal breathing (p < 0.0001) and panting (p < 0.0001). Intra-test variance of SReff and SRtot were similar and showed the lowest percent coefficient of variation during both tidal breathing and panting. Conclusion: Panting and tidal breathing manoeuvres are not interchangeable in COPD patients. Panting widens the clubbing in the SRaw loop. SR0.5 and SRmid may underestimate abnormal physiology in COPD. Plain Language Summary: The effort to breathe can be measured as specific airway resistance (SRaw), which is a measure of the airflow that a person can achieve. SRaw is calculated from a plotted loop, but may be affected by the way that the test is performed and calculated. SRaw can be measured during panting or tidal breathing, and can be calculated using different methods of plotting the SRaw slope. In COPD patients, we found that panting SRaw is higher than during tidal breathing, and the calculation methods that use the extremities of the SRaw loop give higher values and have the lowest variability.